5-hydroxymethyl-2,2,7,8-tetramethyl-chroman-6-ol | 28358-00-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 5-hydroxymethyl-2,2,7,8-tetramethyl-chroman-6-ol
• 英文别名: 3,4-Dihydro-6-hydroxy-2,2,7,8-tetramethyl-2H-1-benzopyran-5-methanol；5-(hydroxymethyl)-2,2,7,8-tetramethyl-3,4-dihydrochromen-6-ol
• CAS: 28358-00-1
• 化学式: C₁₄H₂₀O₃
• 分子量: 236.311
• InChiKey: WLKWXLDDBKOJAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3,4-二氢-2,2,5,7,8-五甲基-2H-1-苯并吡喃-6-酚 生成 5-hydroxymethyl-2,2,7,8-tetramethyl-chroman-6-ol
  参考文献：
  名称：

  SUARNA, SUMARNO CACANG;NELSON, DEREK;SOUTHWELL-KEELY, PETER T., LIPIDS, 23,(1988) N2, C. 1129-1131

  摘要：

  DOI：

文献信息

• Treatment of mitochondrial diseases
  申请人：Walkinshaw Gail

  公开号：US20050065099A1

  公开（公告）日：2005-03-24

  The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein.

  这项发明涉及治疗或改善线粒体疾病，如阿尔茨海默病、帕金森病、弗里德雷希共济失调症（FRDA）、小脑共济失调、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）、带有红色纤维的肌阵挛性癫痫（MERFF）、肌萎缩侧索硬化症（ALS）、运动神经元疾病、亨廷顿病、黄斑变性和癫痫等疾病的治疗方法，所述方法使用本文描述的Formula I或Formula II的类胡萝卜素衍生物。
• Chroman derivatives for the reduction of inflammation symptoms
  申请人：——

  公开号：US20040097433A1

  公开（公告）日：2004-05-20

  The present invention provides a composition comprising chroman derivatives, for use in the reduction of inflammatory markers associated with inflammation, particularly for the reduction of C-reactive protein (CRP) and for use in the treatment and/or amelioration of symptoms of inflammation.

  本发明提供一种包含香豆素衍生物的组合物，用于减少与炎症相关的炎症标志物，特别是用于减少C-反应蛋白(CRP)，并用于治疗和/或缓解炎症症状。
• TREATMENT OF MITOCHONDRIAL DISEASES
  申请人：Ampere Life Sciences, Inc.

  公开号：US20130267538A1

  公开（公告）日：2013-10-10

  The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein.

  本发明涉及使用式I或式II所描述的色酮衍生物的治疗或改善线粒体疾病的方法，例如阿尔茨海默病、帕金森病、弗里德雷希共济失调症（FRDA）、小脑共济失调、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）、带红纤维的肌阵挛性癫痫（MERFF）、肌萎缩侧索硬化症（ALS）、运动神经元疾病、亨廷顿病、黄斑退化和癫痫。
• SUARNA, SUMARNO CACANG;NELSON, DEREK;SOUTHWELL-KEELY, PETER T., LIPIDS, 23,(1988) N2, C. 1129-1131
  作者：SUARNA, SUMARNO CACANG、NELSON, DEREK、SOUTHWELL-KEELY, PETER T.

  DOI：——

  日期：——
• PHARMACEUTICALLY ACTIVE COMPOSITIONS COMPRISING OXIDATIVE STRESS MODULATORS (OSM), NEW CHEMICAL ENTITIES, COMPOSITIONS AND USES
  申请人：Basu Hirak S.

  公开号：US20100297262A1

  公开（公告）日：2010-11-25

  Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of inflammation and cancer.